Sales & Marketing | Connecting with physicians and patients

News

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.

News

Norgine gets first EU approval for WHIM syndrome therapy

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

News

AZ will invest £300m in UK, says PM Keir Starmer

AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.

News

First-quarter sales strength buoys new GSK CEO Miels

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.

Sales & Marketing

Changing Faces May-June 2024: Agency, consultancy, and inves...

For a super-sized hires round-up, our list of hires in the agency and consultancy world for May and June is surprisingly concise.

Sales & Marketing

Sponsored

How to harmonise global content strategies with local needs ...

Any pharma business operating on a global scale would naturally strive to execute a uniformed content marketing strategy across all markets.

News

FDA panel backs Zevra's arimoclomol, after earlier rejection

An FDA advisory committee has recommended approval of Zevra Therapeutics' arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.

News

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.

News

Norgine gets first EU approval for WHIM syndrome therapy

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

Press Releases

News

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

Sales & Marketing

Partner Content

Pharma Equipment Auction: Surepharm Assets Sale

Bid on used pharmaceutical production and packaging equipment. View auction April 22-24.

Views & Analysis

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Changing Faces: Agency, consultancy, and investor, March 202...

March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces.

Deep Dive

Sales & Marketing

Deep Dive: Commercialisation 2024

In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.

Sales & Marketing

Five top tips for developing a communication strategy

Sales & Marketing

Assessing the global applicability of the UK’s ‘Netflix’-sty...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Sales & Marketing

Sponsored

Health Trends 2025: Reimagining What's Possible

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl

Podcasts

Sales & Marketing

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Sponsored

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

Sales & Marketing

Sponsored

From Buzzword to Strategy: Reverba Global Talks Omnichannel ...

Video

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Sales & Marketing

Interview at JPM26 with Helen Sabzevari and Greg Skalicky

Rewiring commercialisation to meet the moment, with Helen Sa...

At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.

Sales & Marketing

Sponsored

Bridging science and strategy: Medical Affairs at the heart ...

In this sponsored podcast, Cheryl Lubbert and Carolyn Whiting of Reverba discuss a new approach to pharma marketing, omnichannel, and medical affairs.

White Papers

Sales & Marketing

Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

Sales & Marketing

Lumanity white paper - person at top of mountain range

Sponsored

The strategic imperative of Integrated Evidence Generation P...

Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.

Sales & Marketing

Sponsored

5 strategies to retain top talent

The pharma sales industry is in the midst of rapid transformation, fuelled by digital disruption and dynamic market forces.

Event

Sales & Marketing

Partner Content

The ESG in Life Sciences Summit is coming to the West Coast!

The ESG in Life Sciences Summit West is coming to San Francisco! (July 8-10, 2025).

Sales & Marketing

Reuters Pharma Barcelona 2023 - Day 2

Moving into Day Two – if you missed it, do be sure to catch up on yesterday’s coverage here – pharmaphoru

Debates & Insight

Sponsored

How to optimise pharma’s digital HCP engagement

Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their preferred mix of channels if they are to bridge the gap between the value a compan

Sales & Marketing

Sponsored

An integrated CRM saves time, money and drives sales efficie...

Like most pharmaceutical companies, Théa Pharma places the utmost importance on quality customer data – but non-integrated systems were holding the team back.

Debates & Insight

Ensuring delivery of healthcare professional education

Pharma companies always need to know they can get the right information to the right people at the right time.

Partner Content

Secure Your .med Domain by Pre-Registration

Successful pre-registration guarantees your desired .med domain(s) will be registered only to you when .med opens on 2 September 2025.

Sales & Marketing

Partner Content

The ESG in Life Sciences Summit is coming to the West Coast!

The ESG in Life Sciences Summit West is coming to San Francisco! (July 8-10, 2025).

Sales & Marketing

Partner Content

Pharma Equipment Auction: Surepharm Assets Sale

Bid on used pharmaceutical production and packaging equipment. View auction April 22-24.

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Norgine gets first EU approval for WHIM syndrome therapy

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

AZ will invest £300m in UK, says PM Keir Starmer

First-quarter sales strength buoys new GSK CEO Miels

Changing Faces May-June 2024: Agency, consultancy, and inves...

How to harmonise global content strategies with local needs ...

FDA panel backs Zevra's arimoclomol, after earlier rejection

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Norgine gets first EU approval for WHIM syndrome therapy

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Pharma Equipment Auction: Surepharm Assets Sale

A philosophical look at market turn in the Age of AI, with J...

Changing Faces: Agency, consultancy, and investor, March 202...

Deep Dive: Commercialisation 2024

Five top tips for developing a communication strategy

Assessing the global applicability of the UK’s ‘Netflix’-sty...

Using AI-driven synthetic personas to take your insights fur...

How to meet your physicians where they are online

Health Trends 2025: Reimagining What's Possible

A philosophical look at market turn in the Age of AI, with J...

Pushing through barriers to commercial launch success, with ...

From Buzzword to Strategy: Reverba Global Talks Omnichannel ...

Biotech is back, with Craig Ackerman

Rewiring commercialisation to meet the moment, with Helen Sa...

Bridging science and strategy: Medical Affairs at the heart ...

What HCPs Say Pharma Gets Wrong About Survey Research

The strategic imperative of Integrated Evidence Generation P...

5 strategies to retain top talent

The ESG in Life Sciences Summit is coming to the West Coast!

Reuters Pharma Barcelona 2023 - Day 2

How to optimise pharma’s digital HCP engagement

An integrated CRM saves time, money and drives sales efficie...

Ensuring delivery of healthcare professional education

Secure Your .med Domain by Pre-Registration

The ESG in Life Sciences Summit is coming to the West Coast!

Pharma Equipment Auction: Surepharm Assets Sale

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks